Synthesis and structure-activity relationships of N2-alkylated quaternary β-carbolines as novel antitumor agents

European Journal of Medicinal Chemistry

Volumn 65, Issue , 2013, Pages 21-31

  Zhang, Guoxian ^a   Cao, Rihui ^a   Guo, Liang ^b   Ma, Qin ^b   Fan, Wenxi ^b   Chen, Xuemei ^b   Li, Jianru ^a   Shao, Guang ^a   Qiu, Liqin ^a   Ren, Zhenghua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Xinjiang Huashidan Pharmaceutical Co Ltd   (China)

Author keywords

Antitumor; Cytotoxic; Structure activity relationships; Synthesis; Carboline

Indexed keywords

1 (4 METHOXYPHENYL) BETA CARBOLINE; 1 (METHOXYPHENYL) 9 (3 PHENYLPROPYL)BETA CARBOLINE; 1 (THIOPEN 3 YL) BETA CARBOLINE; 1 METHYL 9 (3 PHENYLPROPYL)BETA CARBOLINE; 1 PHENYL 9 (3 PHENYLPROPYL)BETA CARBOLINE; 1 PHENYL BETA CARBOLINE; 2 BENZYL 9 ALLYL BETA CARBOLINIUM BROMIDE; 2 BENZYL 9 BUTYL BETA CARBOLINIUM BROMIDE; 2 BENZYL 9 ETHYL BETA CARBOLINIUM BROMIDE; 2 BENZYL 9 HEXYL BETA CARBOLINIUM BROMIDE; 2 BENZYL 9 ISOBUTYL BETA CARBOLINIUM BROMIDE; 2 BENZYL 9 ISOPROPYL BETA CARBOLINIUM BROMIDE; 2 BENZYL 9 METHYL BETA CARBOLINIUM BROMIDE; 2 BENZYL 9 OCTYL BETA CARBOLINIUM BROMIDE; 9 (3 CHLOROBENZYL)L BETA CARBOLINE; 9 (3 PHENYLPROPYL) 1 (THIOPEN 3 YL) BETA CARBOLINE; 9 (3 PHENYPROPYL) BETA CARBOLINE; 9 (4 CHLOROBENZYL) 2 BENZYL BETA CARBOLINIUM BROMIDE; 9 (4 FLUOROBENZYL) 2 BENZYL BETA CARBOLINIUM BROMIDE; 9 (4 FLUOROBENZYL)L BETA CARBOLINE; 9 (4 METHOXYBENZYL) 2 BENZYL BETA CARBOLINIUM BROMIDE; 9 (4 METHOXYBENZYL) BETA CARBOLINE; 9 ALLYL BETA CARBOLINE; 9 HEXYL BETA CARBOLINE; 9 ISOBUTYL BETA CARBOLINE; 9 ISOPROPYL BETA CARBOLINE; 9 OCTYL BETA CARBOLINE; ANTINEOPLASTIC AGENT; BETA CARBOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE TOXICITY; ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEWIS CARCINOMA; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SARCOMA 180; STRUCTURE ACTIVITY RELATION;

EID: 84884271207     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.04.031     Document Type: Article

References (41)

1. R. Cao, W. Peng, Z. Wang, A. Xu, β-Carboline alkaloids: biochemical and pharmacological functions, Curr. Med. Chem. 14 (2007) 479-500.
2. J. Ishida, H.-K. Wang, K.F. Bastow, C.-Q. Hu, K.-H. Lee, Antitumor agents 201, cytotoxicity of harmine and β-carboline analogs, Bioorg. Med. Chem. Lett. 9 (1999) 3319-3324.
3. S. Xiao, W. Lin, C. Wang, M. Yang, Synthesis and biological evaluation of DNA targeting flexible side-chain substituted β-carboline derivatives, Bioorg. Med. Chem. Lett. 11 (2001) 437-441.
4. Y. Song, J. Wang, S.F. Teng, D. Kesuma, Y. Deng, J. Duan, J.H. Wang, R.Z. Qi, M.M. Sim, β-Carboline as speci fic inhibitors of cyclin-dependent kinases, Bioorg. Med. Chem. Lett. 12 (2002) 1129-1132.
5. M. Zhao, L. Bi, W. Wang, C. Wang, M. Baudy-Floch, J. Ju, S. Peng, Synthesis and cytotoxic activities of β-carboline amino acid ester conjugates, Bioorg. Med. Chem. 18 (2006) 6998-7010.
6. A.S.N. Formagio, L.T.D. Tonin, M.A. Foglio, C. Madjarof, J.E. de Carvalho, W.F. da Costa, F.P. Cardoso, M.H. Sarragiotto, Synthesis and antitumoral activity of novel 3-(2-substituted-1,3,4-oxadiazol-5-yl) and 3-(5-substituted- 1,2,4-triazol-3-yl) β-carboline derivatives, Bioorg. Med. Chem. 16 (2008) 9660-9667.
7. J. Wu, M. Zhao, K. Qian, K.-H. Lee, S. Morris-Natschke, S. Peng, Novel N-(3-carboxyl-9-benzyl-β-carboline-1-yl)ethylamino acids: synthesis, anti-tumor evaluation, intercalating determination, 3D QSAR analysis and docking investigation, Eur. J. Med. Chem. 44 (2009) 4153-4161.
8. R. Ikeda, M. Kurosawa, T. Okabayashi, A. Takei, M. Yoshiwara, T. Kumakura, N. Sakai, O. Funatsu, A. Morita, M. Ikekita, Y. Nakaike, T. Konakahara, 3-(3-Phenoxybenzyl)amino-β-carboline: a novel antitumor drug targeting α-tubulin, Bioorg. Med. Chem. Lett. 21 (2011) 4784-4787.
9. M. Yang, P.-C. Kuo, T.-L. Hwang, W.-F. Chiou, K. Qian, C.-Y. Lai, K.-H. Lee, T.-S. Wu, Synthesis, in vitro anti-inflammatory and cytotoxic evaluation, and mechanism of action studies of 1-benzoyl-β-carboline and 1-benzoyl-3- carboxy-β-carboline derivatives, Bioorg. Med. Chem. 19 (2011) 1674-1682.
10. G. Duportail, Linear and circular dichroism of harmine and harmaline interacting with DNA, Int. J. Biol. Macromol. 3 (1981) 188-193.
11. Z. Taira, S. Kanzawas, C. Dohara, S. Ishida, M. Matsumoto, Y. Sakiya, Intercalation of six beta-carboline derivatives into DNA, Jpn. J. Toxicol. Environ. Health 43 (1997) 83-91.
12. Y. Funayama, K. Nishio, K. Wakabayashi, M. Nagao, K. Shimoi, T. Ohira, S. Hasegawa, M. Saijo, Effects of β and γ-carboline derivatives on DNA topoisomerase activities, Mutat. Res. 349 (1996) 183-191.
13. A.M. Sobhani, S.A. Ebrahimi, M. Mahmoudian, An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its β-carboline alkaloids, J. Pharm. Pharm. Sci. 5 (2002) 19-23.
14. R. Cao, W. Peng, H. Chen, Y. Ma, X. Liu, X. Hou, H. Guan, A. Xu, DNA binding properties of 9-substituted harmine derivatives, Biochem. Biophys. Res. Commun. 338 (2005) 1557-1563.
15. Y. Song, D. Kesuma, J. Wang, Y. Deng, J. Duan, J.H. Wang, R.Z. Qi, Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine, Biochem. Biophys. Res. Commun. 317 (2004) 128-132.
16. Y. Li, F. Liang, W. Jiang, F. Yu, R. Cao, Q. Ma, X. Dai, J. Jiang, Y. Wang, S. Si, DH334, a β-carboline anti-cancer drug, inhibits the CDK activity of budding yeast, Cancer Biol. Ther. 6 (2007) 1193-1199.
17. J.I. Trujillo, M.J. Meyers, D.R. Anderson, S. Hegde, M.W. Mahoney, W.F. Vernier, I.P. Buchler, K.K. Wu, S. Yang, S.J. Hartmann, D.B. Reitz, Novel tetrahydro-β-carboline- 1-carboxylic acids as inhibitors of mitogen activated protein kinaseactivated protein kinase 2 (MK-2), Bioorg.Med. Chem. Lett. 17 (2007) 4657-4663.
18. P.A. Barsanti, W. Wang, Z. Ni, D. Duhl, N. Brammeier, E. Martin, The discovery of tetrahydro-β-carbolines as inhibitors of the kinesin Eg5, Bioorg, Med. Chem. Lett. 20 (2010) 157-160.
19. A.C. Castro, L.C. Dang, F. Soucy, L. Grenier, H. Mazdiyasni, M. Hottelet, L. Parent, C. Pien, V. Palombella, J. Adams, Novel IKK inhibitors: β-carbolines, Bioorg. Med. Chem. Lett. 13 (2003) 2419-2422.
20. R. Cao, Q. Chen, X. Hou, H. Chen, H. Guan, Y. Ma, W. Peng, A. Xu, Synthesis, acute toxicities and antitumor effects of novel 9-substituted β-carboline derivatives, Bioorg. Med. Chem. 12 (2004) 4613-4623.
21. R. Cao, W. Peng, H. Chen, X. Hou, H. Guan, Q. Chen, Y. Ma, A. Xu, Synthesis and in vitro cytotoxic evaluation of 1,3-bisubstituted and 1,3,9-trisubstituted β-carboline derivatives, Eur. J. Med. Chem. 40 (2005) 249-257.
22. R. Cao, H. Chen, W. Peng, Y. Ma, X. Hou, H. Guan, X. Liu, A. Xu, Design, synthesis and in vitro and in vivo antitumor activities of novel β-carboline derivatives, Eur. J. Med. Chem. 40 (2005) 991-1001.
23. H. Guan, H. Chen, W. Peng, Y. Ma, R. Cao, X. Liu, A. Xu, Design of β-carboline derivatives as DNA-targeting antitumor agents, Eur. J. Med. Chem. 41 (2006) 1167-1179.
24. R. Cao, W. Yi, Q. Wu, X. Guan, M. Feng, C. Ma, Z. Chen, H. Song, W. Peng, Synthesis and cytotoxic activities of 1-benzylidine substituted β-carboline derivatives, Bioorg. Med. Chem. Lett. 18 (2008) 6558-6561.
25. Q. Wu, R. Cao, M. Feng, X. Guan, C. Ma, J. Liu, H. Song, W. Peng, Synthesis and in vitro cytotoxic evaluation of novel 3,4,5-trimethoxyphenyl substituted β-carboline derivatives, Eur. J. Med. Chem. 44 (2009) 533-540.
26. 2-benzylated quaternary β-carboline amino acid ester conjugates, Eur. J. Med. Chem. 45 (2010) 1515-1523.
27. R. Cao, X. Guan, B. Shi, Z. Chen, Z. Ren, W. Peng, H. Song, Design, synthesis and 3D-QSAR of β-carboline derivatives as potent antitumor agents, Eur. J. Med. Chem. 45 (2010) 2503-2515.
28. Z. Chen, R. Cao, B. Shi, Y. Wei, L. Yu, H. Song, Z. Ren, W. Peng, Synthesis of novel β-carbolines with efficient DNA-binding capacity and potent cytotoxicity, Bioorg. Med. Chem. Lett. 20 (2010) 3876-3879.
29. Z. Chen, R. Cao, L. Yu, B. Shi, J. Sun, L. Guo, Q. Ma, W. Yi, X. Song, H. Song, Synthesis, cytotoxic activities and DNA binding properties of β-carboline derivatives, Eur. J. Med. Chem. 45 (2010) 4740-4745.
30. C. Ma, R. Cao, B. Shi, X. Zhou, Q. Ma, J. Sun, L. Guo, W. Yi, Z. Chen, H. Song, Synthesis and cytotoxic evaluation of 1-carboxamide and 1-amino side chain substituted β-carbolines, Eur. J. Med. Chem. 45 (2010) 5513-5519.
31. Z. Chen, R. Cao, B. Shi, L. Guo, J. Sun, Q. Ma, W. Fan, H. Song, Synthesis and biological evaluation of 1,9-disubstituted β-carbolines as potent DNA intercalating and cytotoxic agents, Eur. J. Med. Chem. 46 (2011) 5127-5137.
32. R. Cao, W. Fan, L. Guo, Q. Ma, G. Zhang, J. Li, X. Chen, Z. Ren, L. Qiu, Synthesis and structure-activity relationships of harmine derivatives as potential antitumor agents, Eur. J. Med. Chem. 60 (2013) 135-143.
33. F.A. Barr, H.H.W. Silljè, E.A. Nigg, Polo-like kinases and the orchestration of cell division, Nat. Rev. Mol. Cell. Biol. 5 (2004) 429-440.
34. H.A. Lane, E.A. Nigg, Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes, J. Cell. Biol. 135 (1996) 1701-1713.
35. M.A. van Vugt, Weerdt B.C. van de, G. Vader, H. Janssen, J. Calafat, R. Klompmaker, R.M. Wolthuis, R.H. Medema, Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis, J. Biol. Chem. 279 (2004) 36841-36854.
36. B. Spankuch-Schmitt, G. Wolf, C. Solbach, S. Loibl, R. Knecht, M. Stegmuller, G. von Minckwitz, M. Kaufmann, K. Strebhardt, Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells, Oncogene 21 (2002) 3162-3171.
37. X. Liu, R.L. Erikson, Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5789-5794.
38. R. Guan, P. Tapang, J.D. Leverson, D. Albert, V.L. Giranda, Y. Luo, Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals, Cancer Res. 65 (2005) 2698-2704.
39. J. Zhang, Y. Li, L. Guo, R. Cao, P. Zhao, W. Jiang, Q. Ma, H. Yi, Z. Li, J. Jiang, J. Wu, Y. Wang, S. Si, DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1, Cancer Biol. Ther. 8 (2009) 2374-2383.
40. X. Han, J. Zhang, L. Guo, R. Cao, Y. Li, N. Li, Q. Ma, J. Wu, Y. Wang, S. Si, A series of beta-carboline derivatives inhibit the kinase activity of PLKs, PLoS One 7 (2012) e46546.
41. J. Kassa, J. Vachek, A comparison of the efficacy of pyridostigmine alone and the combination of pyridostigmine with anticholinergic drugs as pharmacological pretreatment of tabun-poisoned rats and mice, Toxicology 177 (2002) 179-185.